Lupin could break its ATH in next year. Target 1 is 1400. Has potential for 2x.
View negated if US FDA, or other factors break the pattern.
Lupin sees strong traction for its India business and expects growth to be in the high-teens in FY2022, which would be driven by strong growth in the base business, especially chronic therapies. The US business is expected to be impacted by the price erosion in the near term while 2HFy2022 is expected to see a marked improvement driven by ramp up in Albuterol and Brovana. High potential / limited competition launches in FY23 provide further visibility for growth.
View negated if US FDA, or other factors break the pattern.
Lupin sees strong traction for its India business and expects growth to be in the high-teens in FY2022, which would be driven by strong growth in the base business, especially chronic therapies. The US business is expected to be impacted by the price erosion in the near term while 2HFy2022 is expected to see a marked improvement driven by ramp up in Albuterol and Brovana. High potential / limited competition launches in FY23 provide further visibility for growth.
Lupin could break its 52 week high ** in next year (2022). Target 1 is 1400. Has potential for 2x.
Target 2 is for 2022-23
Targer 3 is for 2024